Literature DB >> 21951273

VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Alain Couvineau1, Marc Laburthe.   

Abstract

The vasoactive intestinal peptide (VIP) is a neuropeptide with wide distribution in both central and peripheral nervous systems, where it plays important regulatory role in many physiological processes. VIP displays a large biological functions including regulation of exocrine secretions, hormone release, fetal development, immune responses, etc. VIP appears to exert beneficial effect in neuro-degenerative and inflammatory diseases. The mechanism of action of VIP implicates two subtypes of receptors (VPAC1 and VPAC2), which are members of class B receptors belonging to the super-family of GPCR. This article reviews the current knowledge regarding the structure and molecular pharmacology of VPAC receptors. The structure-function relationship of VPAC1 receptor has been extensively studied, allowing to understand the molecular basis for receptor affinity, specificity, desensitization and coupling to adenylyl cyclase. Those studies have clearly demonstrated the crucial role of the N-terminal ectodomain (N-ted) of VPAC1 receptor in VIP recognition. By using different approaches including directed mutagenesis, photoaffinity labelling, NMR, molecular modelling and molecular dynamic simulation, it has been shown that the VIP molecule interacts with the N-ted of VPAC1 receptor, which is itself structured as a 'Sushi' domain. VPAC1 receptor also interacts with a few accessory proteins that play a role in cell signalling of receptors. Recent advances in the structural characterization of VPAC receptor and more generally of class B GPCRs will lead to the design of new molecules, which could have considerable interest for the treatment of inflammatory and neuro-degenerative diseases.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21951273      PMCID: PMC3415636          DOI: 10.1111/j.1476-5381.2011.01676.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  70 in total

1.  Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis.

Authors:  Catalina Abad; Yossan-Var Tan; Robert Lopez; Hiroko Nobuta; Hongmei Dong; Phu Phan; Ji-Ming Feng; Anthony T Campagnoni; James A Waschek
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-26       Impact factor: 11.205

2.  Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP.

Authors:  A Couvineau; P Gaudin; J J Maoret; C Rouyer-Fessard; P Nicole; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1995-01-05       Impact factor: 3.575

3.  VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.

Authors:  Mahesh Yadav; Mei-Chuan Huang; Edward J Goetzl
Journal:  Cell Immunol       Date:  2011-01-07       Impact factor: 4.868

4.  Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains.

Authors:  A Couvineau; C Rouyer-Fessard; D Darmoul; J J Maoret; I Carrero; E Ogier-Denis; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1994-04-29       Impact factor: 3.575

Review 5.  Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues.

Authors:  R M Campbell; J Bongers; A M Felix
Journal:  Biopolymers       Date:  1995       Impact factor: 2.505

6.  Identification and characterization of a small molecule antagonist of human VPAC(2) receptor.

Authors:  Alan Chu; Jeremy S Caldwell; Yu Alice Chen
Journal:  Mol Pharmacol       Date:  2009-10-23       Impact factor: 4.436

7.  Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.

Authors:  I Gozes; A Bardea; A Reshef; R Zamostiano; S Zhukovsky; S Rubinraut; M Fridkin; D E Brenneman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 8.  VPAC1 receptor binding site: contribution of photoaffinity labeling approach.

Authors:  A Couvineau; E Ceraudo; Y-V Tan; M Laburthe
Journal:  Neuropeptides       Date:  2009-12-23       Impact factor: 3.286

9.  Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by class B G-protein coupled receptors.

Authors:  Shiva Kumar; Augen Pioszak; Chenghai Zhang; Kunchithapadam Swaminathan; H Eric Xu
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

10.  Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia.

Authors:  Vladimir Vacic; Shane McCarthy; Dheeraj Malhotra; Fiona Murray; Hsun-Hua Chou; Aine Peoples; Vladimir Makarov; Seungtai Yoon; Abhishek Bhandari; Roser Corominas; Lilia M Iakoucheva; Olga Krastoshevsky; Verena Krause; Verónica Larach-Walters; David K Welsh; David Craig; John R Kelsoe; Elliot S Gershon; Suzanne M Leal; Marie Dell Aquila; Derek W Morris; Michael Gill; Aiden Corvin; Paul A Insel; Jon McClellan; Mary-Claire King; Maria Karayiorgou; Deborah L Levy; Lynn E DeLisi; Jonathan Sebat
Journal:  Nature       Date:  2011-02-23       Impact factor: 49.962

View more
  43 in total

1.  Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.

Authors:  David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Circuit development in the master clock network of mammals.

Authors:  Vania Carmona-Alcocer; Kayla E Rohr; Deborah A M Joye; Jennifer A Evans
Journal:  Eur J Neurosci       Date:  2018-12-05       Impact factor: 3.386

4.  Effects of VPAC1 activation in nucleus ambiguus neurons.

Authors:  Florin Liviu Gherghina; Andrei Adrian Tica; Elena Deliu; Mary E Abood; G Cristina Brailoiu; Eugen Brailoiu
Journal:  Brain Res       Date:  2016-12-30       Impact factor: 3.252

Review 5.  Collective timekeeping among cells of the master circadian clock.

Authors:  Jennifer A Evans
Journal:  J Endocrinol       Date:  2016-05-06       Impact factor: 4.286

6.  Receptor selectivity from minimal backbone modification of a polypeptide agonist.

Authors:  Shi Liu; Ross W Cheloha; Tomoyuki Watanabe; Thomas J Gardella; Samuel H Gellman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-15       Impact factor: 11.205

7.  3D structure prediction of VAPC1 and identification of dual natural inhibitors for VPAC1 and EGFR.

Authors:  Avipsha Sarkar; Shampa Sen
Journal:  J Bioenerg Biomembr       Date:  2019-02-27       Impact factor: 2.945

8.  The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.

Authors:  A Vaczy; D Reglodi; T Somoskeoy; K Kovacs; E Lokos; E Szabo; A Tamas; T Atlasz
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

9.  Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Authors:  Rebeca Jimeno; Javier Leceta; Carmen Martínez; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Marina Garín; Mario Mellado; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2014-05-08       Impact factor: 3.444

10.  The role of VIP in cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Megan E Foldenauer; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.